Clinical Trial Update: MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating hematopoietic cell transplantation with reduced-intensity conditioning and post-transplant cyclophosphamide for severe aplastic anemia …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Amegakaryocytic Thrombocytopenia
• Acquired Pure Red Cell Aplasia
• Aplastic Anemia
• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia | Phase 2 | Status: RECRUITING